Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
41.2M
-
Shares change
-
+1.48M
-
Total reported value, excl. options
-
$2.75B
-
Value change
-
+$112M
-
Put/Call ratio
-
0.01
-
Number of buys
-
70
-
Number of sells
-
-46
-
Price
-
$66.64
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q3 2021
141 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q3 2021.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41.2M shares
of 72.2M outstanding shares and own 57.1% of the company stock.
Largest 10 shareholders include FMR LLC (6.76M shares), Matrix Capital Management Company, LP (4.35M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.73M shares), VANGUARD GROUP INC (3.13M shares), BlackRock Inc. (2.76M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2.66M shares), Avidity Partners Management LP (2.49M shares), VIKING GLOBAL INVESTORS LP (2.12M shares), PRIMECAP MANAGEMENT CO/CA/ (1.34M shares), and STATE STREET CORP (1.29M shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.